Long-term outcome of polymyositis treated with high single-dose alternate-day prednisolone therapy

European Neurology

Volumn 68, Issue 2, 2012, Pages 117-121

  Uchino, Makoto ^a,b   Yamashita, Satoshi ^a   Uchino, Katsuhisa ^a,b   Hara, Akio ^a   Koide, Tatsuya ^a,b   Suga, Tomohiro ^a   Hirahara, Tomoo ^a   Kimura, En ^a   Yamashita, Taro ^a   Ueda, Akihiko ^a   Kurisaki, Ryoichi ^a   Suzuki, Junko ^a   Honda, Shoji ^a   Maeda, Yasushi ^a   Hirano, Teruyuki ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Jonan Hospital   (Japan)

Author keywords

Daily dose prednisolone therapy; High single dose alternate day prednisolone therapy; Polymyositis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; LIVER ABSCESS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OSTEOPOROSIS; PERITONITIS; PNEUMONIA; POLYMYOSITIS; PRIORITY JOURNAL; SEPSIS; SINGLE DRUG DOSE; STOMACH ULCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; DIABETES MELLITUS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYMYOSITIS; PREDNISOLONE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84863754787     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000338474     Document Type: Article

References (28)

1. Harter JG, Reddy WJ, Thorn GW: Studies on an intermittent corticosteroid dosage regimen. N Engl J Med 1963; 269: 591-596.
2. Uchino M, Araki S, Yoshida O, Uekawa K, Nagata J: High single-dose alternate-day corticosteroid regimens in treatment of polymyositis. J Neurol 1985; 232: 175-178. (Pubitemid 15025349)
3. Dalakas MC, Hohlfeld R: Polymyositis and dermatomyositis. Lancet 2003; 362: 971-982. (Pubitemid 37159295)
4. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, Rowland LP: Inclusion body myositis and myopathies. Ann Neurol 1995; 38: 705-713.
5. Karpati G, O'Ferrall EK: Sporadic inclusion body myositis: Pathogenic considerations. Ann Neurol 2009; 65: 7-11.
6. Miller T, Al-Lozi MT, Lopate G, Pestronk A: Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73: 420-428.
7. Dimitri D, Andre C, Roucoules J, Hosseini H, Humbel RL, Authier FJ: Myopathy associated with anti-signal recognition peptide antibodies: clinical heterogeneity contrasts with stereotyped histopathology. Muscle Nerve 2007; 35: 389-395. (Pubitemid 46364097)
8. Suzuki S, Satoh T, Sato S, Otomo M, Hirayama Y, Sato H, Kawai M, Ishihara T, Suzuki N, Kuwana M: Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies. Rheumatology (Oxford) 2008; 47: 1539-1542.
9. Kogan AD, Orenstein S: Lovastatin-induced acute rhabdomyolysis. Postgrad Med J 1990; 66: 294-296. (Pubitemid 20110237)
10. Mohaupt MG, Karas RH, Babiychuk EB, Sanchez-Freire V, Monastyrskaya K, Iyer L, Hoppeler H, Breil F, Draeger A: Association between statin-associated myopathy and skeletal muscle damage. CMAJ 2009; 181:E11-E18.
11. Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A: Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 1998; 50: 764-767.
12. Sampson JB, Smith SM, Smith AG, Singleton JR, Chin S, Pestronk A, Flanigan KM: Paraneoplastic myopathy: response to intravenous immunoglobulin. Neuromuscul Disord 2007; 17: 404-408. (Pubitemid 46679235)
13. Rose AL, Walton JN: Polymyositis: A survey of 89 cases with particular reference to treatment and prognosis. Brain 1966; 89: 747-768.
14. Axelrod L: Glucocorticoid Therapy. Medicine (Baltimore) 1976; 55: 39-65.
15. Cook JD, Trotter JL, Engel WK, Sciabbarrasi JS: The effects of single-dose alternate-day prednisone therapy on the immunological status of patients with neuromuscular diseases. Ann Neurol 1978; 3: 166-176.
16. Fauci AS, Dale DC, Balow JE: Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 1976; 84: 304-315.
17. Streeten DH: Corticosteroid therapy. I. Pharmacological properties and principles of corticosteroid use. JAMA 1975; 232: 944-947.
18. Mastaglia FL, Zilko PJ: Inflammatory myopathies: How to treat the difficult cases. J Clin Neurosci 2003; 10: 99-101. (Pubitemid 35453259)
19. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, Mc-Crosky S: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000. (Pubitemid 24015043)
20. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE: Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999; 353: 1762-1763. (Pubitemid 29240378)
21. Nadiminti U, Arbiser JL: Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. J Am Acad Dermatol 2005; 52: 17-19.
22. Levine TD: Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52: 601-607. (Pubitemid 40216325)
23. Majithia V, Harisdangkul V: Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005; 44: 386-389. (Pubitemid 40361299)
24. Labioche I, Liozon E, Weschler B, Loustaud-Ratti V, Soria P, Vidal E: Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology (Oxford) 2004; 43: 531-532. (Pubitemid 38489380)
25. Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM: Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 1996; 14: 263-274. (Pubitemid 26290866)
26. Benbassat J, Gefel D, Larholt K, Sukenik S, Morgenstern V, Zlotnick A: Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum 1985; 28: 249-255. (Pubitemid 15133568)
27. Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, Courtois H: Polymyositis and dermatomyositis: short-term and long-term outcome, and predictive factors of prognosis. J Rheumatol 2001; 28: 2230-2237. (Pubitemid 32947868)
28. Airio A, Kautiainen H, Hakala M: Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006; 25: 234-239. (Pubitemid 43372323)